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Abstract
Background: Theracyte is a polytetrafluoroethylene membrane macroencapsulation system designed to induce
neovascularization at the tissue interface, protecting the cells from host’s immune rejection, thereby circumventing
the problem of limited half-life and variation in circulating levels. Endostatin is a potent inhibitor of angiogenesis
and tumor growth. Continuous delivery of endostatin improves the efficacy and potency of the antitumoral
therapy. The purpose of this study was to determine whether recombinant fibroblasts expressing endostatin
encapsulated in Theracyte immunoisolation devices can be used for delivery of this therapeutic protein for
treatment of mice bearing B16F10 melanoma and Ehrlich tumors.
Results: Mice were inoculated subcutaneously with melanoma (B16F10 cells) or Ehrlich tumor cells at the foot
pads. Treatment began when tumor thickness had reached 0.5 mm, by subcutaneous implantation of 10
7
recombinant encapsulated or non-encapsulated endostatin producer cells. Similar melanoma growth inhibition was
obtained for mice treated with encapsulated or non-encapsulated endostatin-expressing cells. The treatment of
mice bearing melanoma tumor with encapsulated endostatin-expressing cells was decreased by 50.0%, whereas a
decrease of 56.7% in tumor thickness was obtained for mice treated with non-encapsulated cells. Treatment of
Ehrlich tumor-bearing mice with non-encapsulated endostatin-expressing cells reduced tumor thickness by 52.4%,
whereas lower tumor growth inhibition was obtained for mice treated with encapsulated endostatin-expressing
cells: 24.2%. Encapsulated endostatin-secreting fibroblasts failed to survive until the end of the treatment. However,
endostatin release from the devices to the surrounding tissues was confirmed by immunostaining. Decrease in
vascular structures, functional vessels and extension of the vascular area were observed in melanoma
microenvironments.
Conclusions: This study indicates that immunoisolation devices containing endostatin-expressing cells are effective
for the inhibition of the growth of melanoma and Ehrlich tumors.
Macroencapsulation of engineered cells is therefore a reliable platform for the refinement of innovative therapeutic
strategies against tumors.
Background
Angiogenesis, the formation of new blood vessels from
existing capillaries, is required for tumors to expand
beyond 1-2 mm
3 in size. It is also essential for the
growth and persistence of solid tumors and their metas-
tases [1-3]. Endostatin is a specific angiogenesis inhibitor
that prevents vascular endothelial cells from proliferat-
ing and migrating in response to proangiogenic proteins.
This inhibitor can potently prevent tumor growth
without inducing toxicity or acquired drug resistance
[4,5]. However, injection of endostatin leads to its rapid
clearing from the circulation [6].
Encapsulation of recombinant cells expressing therapeu-
tic proteins within semi-permeable devices for in vivo pro-
tein delivery to systemic circulation is a potentially
sustainable, long-term release system. The semi-permeable
membrane allows for the exchange of nutrients and oxy-
gen between the implanted cells and the host, besides pro-
tecting the cells from rejection by the immune system.
This system can circumvent the problems of limited half-
lives and variation in circulating levels of therapeutically
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tumors using the local delivery of endostatin by either
implantation of alginate microcapsules containing geneti-
cally engineered cells that can produce this protein in the
vicinity of the tumor site [6,7] or transplantation of these
devices into the peritoneal cavities of model animals
[8-10]. However, there is no possibility of withdrawing the
alginate microcapsules containing the genetically engi-
neered cells in case of undesired side effects. Another
likely problem is the possibility of a rupture of the micro-
capsules and liberation of the genetically engineered cells,
which leads to attack from the host’si m m u n es y s t e m .
The Theracyte™ immunoisolation device is a polytetra-
fluoroethylene (PTFE) membrane macroencapsulation
system comprised of a 0.4-μm pore cell-impermeable
membrane, laminated to a 5-mm pore membrane. The
microarchitecture of this membrane is designed to
induce neovascularization at the tissue interface, and it
can also protect the cells from host’s immune rejection,
thereby circumventing the problem of limited half-life.
This membrane has been developed for implantation of
cells capable of producing therapeutic proteins [11].
Besides, this device allows for high density packing of
encapsulated cells in a relatively small area, and it has
been found to be allo-protective [12]. The Theracyte
device can be easily removed altogether with the cells in
the case of undesired side effects or at the end of the
treatment.
In the present study, mice fibroblasts (LM Murine
fibroblast cells) engineered for continuous endostatin
secretion were encapsulated in Theracyte™ immunoisola-
tion devices subcutaneously implanted in mice at a site
distant from the tumors. Aiming at optimizing the anti-
tumor treatment, two protocols were tested for implan-
tation of the cells within the membranes. In the first
protocol, the devices were pre-implanted in the animals
and, after wound healing and tumor growth to a thick-
ness of 0.5 mm (approximately 14 days), the endostatin
producer cells were injected inside these devices. In the
second protocol, the endostatin producer cells were
injected into the devices, which were then implanted in
the mice that already presented a tumor. The ability of
the non-encapsulated and encapsulated cells to secrete
biologically active endostatin capable of inhibiting tumor
growth was evaluated.
Results
Formation of blood vessels occurs in the stroma in the
vicinity of the devices
An important factor related to the survival of recombi-
nant cells is the proper delivery of oxygen and nutrients
to the cells inside the macroimmunoisolation devices.
Theracyte devices are designed to induce the formation
of vascular structures in its vicinity.
One way to circumvent the possible negative effect of
endostatin secreted by the cells inside the device on its
own, via reduced vascularization around the devices,
was to pre-implant empty immunoisolation devices in
the animals, followed by induction of the Ehrlich or
melanoma tumors after an adequate time. Treatment
was initiated when the tumor thickness had reached
0.5 mm, by injecting cells expressing endostatin into the
pre-implanted devices, approximately 14 days after
device implantation. In order to verify whether the pre-
implantation of the devices is necessary, implantation of
devices already containing endostatin producer cells was
also performed for melanoma tumors, despite the possi-
ble deleterious effect of endostatin on the neovasculari-
zation of the wounds. To this end, treatment began by
implanting Theracyte devices already containing the
endostatin-expressing cells after the melanoma had
grown to 0.5 mm thickness. Withdrawal of the devices
was performed on the 14
th treatment day. The presence
of blood vessels, indicative of neovascularization, was
observed in the stroma in the vicinity of the immunoiso-
lation system for both protocols of implantation of the
H.E.-stained slices (Figures 1A and 1B). However, appar-
e n t l yn ov i a b l ec e l l sc o u l db ed e t e c t e di nt h ei n t e r i o ro f
the devices. Adhesion of LM cells to the internal face of
the device membrane was seen, since this is probably
the area with larger readiness of oxygen and nutrients.
Tumor growth is reduced by treatment with
endostatin-expressing cells
The treatment of mice bearing Ehrlich or melanoma
tumors with encapsulated or non-encapsulated cells
began when tumor thicknesses at the pads had reached
0.5 mm.
Ehrlich tumor growth inhibition was observed for mice
treated with LM(pSecTag-end) non-encapsulated cells.
The average of Ehrlich tumor thickness at the mice pads
was 1.28 ± 0.28 mm and 2.69 ± 1.13 mm for the treated
and mock-treated groups of non-encapsulated cells,
respectively, at day 17 (Figure 2A). However, tumors
were observed where LM(pSecTag-end) or LM(pSecTag)
cells were injected. A lower tumor growth inhibition was
obtained for Ehrlich tumor-bearing mice treated with
encapsulated endostatin producer cells. An average
tumor thickness of 2.00 ± 0.37 mm and 2.64 ± 0.74 mm
were obtained at day 17 for the animals treated with
encapsulated LM(pSecTag-end) cells and encapsulated
LM(pSecTag) cells, respectively (Figure 2B).
Figure 2C shows the average melanoma tumor thick-
ness at the pads of animals treated with non-encapsu-
lated endostatin-expressing cells. The average thickness
of the tumors in the mice treated with the non-encapsu-
lated LM(pSecTag-end) cells was 4.53 ± 1.31 mm,
whereas the average tumor thickness in the control
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2.54 mm, a growth reduction of 54.7%. Tumor growth
inhibition was also obtained for the mice treated with
encapsulated LM(pSecTag-end) using both protocols of
Theracyte implantation (Figure 2D). The differences
between tumor growth reduction for mice treated with
pre-implanted devices and devices implanted with the
cells were small, although the number of animals was
low, two and three, respectively. The average thickness
of the melanoma tumor of mice treated via injection of
cells into pre-implanted devices was 4.45 ± 0.07 mm
and 7.80 ± 0.14 mm for the treated animals and control
group, respectively. The values of melanoma tumor
thickness obtained in the group treated with devices
implanted simultaneously with the endostatin-producer
cells was 3.55 ± 0.64 mm at day 14.
Endostatin induces inhibition of angiogenesis in the
melanoma tumors
Analysis of the B16-F10 melanoma tumors after 7 days
of treatment using 10
7 non-encapsulated cells was per-
formed, in order to evaluate the efficacy of endostatin
on angiogenesis. The microvascular density was evalu-
ated using the CD34 antibody. Quantitative analysis of
the sections showed a decrease of 41.5% in the number
of vascular structures, 35.9% in the number of functional
vessels, and 33.5% in the extension of the vascular area
compared with the tumors of animals treated with mock
cells (Figure 3). The solid Ehrlich tumor was shown to
be poorly vascularized (data not shown).
Endostatin secreted by the cells inside the devices
reaches the adjacent stroma
Immunohistochemistry with endostatin antibody
revealed a gradual dispersion of this protein in the tissue
around the device (Figure 4), which was withdrawn from
melanoma-bearing mice on the 14
th treatment day. This
result indicates that endostatin secreted by the confined
recombinant cells permeated through the membrane,
outstretching to the surrounding tissues.
Discussion
We describe a therapeutic protocol for the antiangiogenic
treatment of the Ehrlich and melanoma tumors induced
in C3H-HePas and C57Bl/6 mice, respectively. The treat-
ment consists in using endostatin-expressing murine
fibroblasts encapsulated in macroimmunoisolation
devices (Theracyte™). Immunoisolation at sufficiently
high cell densities for practical therapy might be enabled
by membranes that facilitate neovascularization at the
membrane of the device-tissue interface. This is impor-
tant for the sustained supply of oxygen and nutrients to
the cells inside the devices as well as for the delivery of
therapeutic proteins to the surrounding tissues [11]. Low
densities of cells inside macroimmunoisolation devices
can be achieved because of mean oxygen tension result-
ing from poor vascularization in the vicinity of the
implant. Theracyte devices display 5 μm PTFE pores that
stimulate formation of vascular structures via penetration
of host cells. This leads to secretion of angiogenic factors
and/or factors by the host cells, which overcome an exist-
ing inhibition of neovascularization, laminated to smaller
pore (0.4 μm) inner membrane, thereby preventing cell
entry into the immunoisolation devices. In our study,
examination of the local response to the implanted cells
shows the presence of blood vessels in the vicinity of the
devices, ratifying the supposition that the Theracyte™
membrane induces neovascularization in the tissue adja-
cent to it. Our data indicate that, after 14 days, the
encapsulated cells used for the treatment are apparently
Figure 1 The tissue adjacent to the devices was vascularized but cells inside the devices are not viable. (A and B)- Histological analyses
(stained with H.E.) of the environment around the device. Arrows show new blood vessels, which reveals that it is biologically inert and
promotes neovascularization, and that the cells are inside the device. No viable endostatin producer cells were noted; (A) Histological analyses
of the environment around the device which was pre-implanted;(B) Histological analyses of the environment around the device which was
implanted concomitantly with the cells.
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neovascularization, the supply of nutrients and oxygen is
not sufficient to keep transplanted cells alive for a long
time. Nevertheless, the subcutaneous growth of mela-
noma and Ehrlich tumors was inhibited with both proto-
cols used for implantation of immunoisolated endostatin-
secreting cells. The consistent effect observed in tumor
growth is likely attributable to the elevation of the serum
levels of endostatin. In the first treatment protocol, the
device was pre-implanted and, after wound healing and
neovascularization in the vicinity of the device, the endo-
statin-expressing LM(pSecTag-end) cells were inoculated
into the capsule. Implantation of the device before the
injection of the LM(pSecTag-end) cells aimed at improv-
ing vascularization at the host tissue/device membrane
interface before implantation of the endostatin-secreting
Figure 2 Endostatin delivered by engineered cells impaired tumor growth. (A), Solid lines: control group treated with LM(pSecTag)
non-encapsulated cells (n = 6); Dashed lines: group treated with LM(pSecTag-end) non-encapsulated cells (n = 4); (B), Solid line: control group
treated with LM(pSecTag) encapsulated cells injected into pre-implanted devices (n = 3); Dashed line: group treated with LM(pSecTag-end)
injected into pre-implanted devices (n = 5); (C), Solid lines: control group treated with LM(pSecTag) non-encapsulated cells (n = 4); Dashed lines:
group treated with LM(pSecTag-end) non-encapsulated cells (n = 4); (D), Solid line: control group treated with LM(pSecTag) encapsulated cells
injected into devices which were then implanted into mice (n = 2); Dashed lines: group treated with LM(pSecTag-end) encapsulated cells using
both protocols of implantation (n = 5); Inset D shows the same data as in D, Solid line: control group treated with LM(pSecTag) encapsulated
cells injected into devices which were then implanted into mice (n = 2); Dotted line: group treated with LM(pSecTag-end) encapsulated cells
injected into devices which were then implanted into mice (n = 3); Dashed line: group treated with 10
7 LM(pSecTag-end) encapsulated cells,
injected into the pre-implanted devices (n = 2).
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Page 4 of 9Figure 3 Neovascularization on melanoma tumor was impaired by endostatin. (A and B) - Immunohistochemical analyses of the
melanoma tumor microenvironment, after 7 days of treatment, showing the differences found in the vascular structure in the (A) control mice
treated with LM(pSecTag) cells and (B) mice treated with LM(pSecTag-end) cells. The neovascularization was quantitatively analyzed in the tumor
tissue immunohistochemistry stained using the CD34 antibody (C) Number of vascular structures (n = 5) (p = 0.008) ; (D) Number of functional
vasculature (vessel with erythrocyte inside) (n = 5) (p = 0.047); and (E) vascular area (n = 5) (p = 0.2). Mean +/- SD.
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blood vessel formation, cell viability, and thus response
to the treatment. A 42.4% reduction in melanoma growth
was obtained. Endostatin acts preferentially in tumor
neovascularization [13,14], and the most evident effect of
endostatin on the vascularization of wounds in non-
tumoral woven is the formation of a larger number of
nonfunctional vessels. In the second protocol of tumor
treatment, devices already containing the endostatin-pro-
ducer cells were implanted, and a slightly larger tumor
reduction was obtained for tumor growth: 54.5% at the
14
th treatment day. This result indicates that either the
effect of endostatin was not as significant for neovascu-
larization of normal tissue as it was effective for the treat-
ment of the tumors, or that there are other factors
implicated in the survival of the cells inside the devices.
These factors can possibly supplant the negative effect of
endostatin on the formation of new blood vessels.
Different approaches will be necessary to sustain
endostatin serum levels through larger periods. Replen-
ishing macrocapsules with endostatin producing cells is
among the possible strategies. Despite the limited num-
ber of animals tested in this study, we could show that
filling implanted capsules is possible and yields similar
results as compared with experiments using filled cap-
sules. Alternatively, new devices can be implanted.
Implantation of the immunoisolation devices already
containing the endostatin-producing cells is convenient
because the beginning of the treatment is not delayed
by pre-implantation of the empty device, not to mention
that only one surgery is necessary in this case.
A protocol for endostatin delivery to the systemic cir-
culation of mice using recombinant CHO cells, expres-
sing high endostatin levels, encapsulated in Theracyte™
bioisolating devices was described. Throughout the two-
month study, constant and high endostatin levels of up
to 3.7 μg/ml were detected in the plasma of the mice
implanted with the devices [15]. The use of CHO engi-
neered cells, which apparently are more resistant than
LM to the hypoxic microenvironment of the immunoi-
solation devices is other alternative to keep endostatin
serum levels.
Figure 4 Endostatin is present in the stroma adjacent to the device. (A and B) Immunohistochemical analyses using BSA in the tissue
around the devices with (A) LM(pSecTag) cells; (B) LM (pSecTag-end) cells, showing the absence of reaction in the stroma adjacent to the
devices; (C and D)- Immunohistochemical analyses using endostatin antibody of the environment around the device; (C) Immunohistochemical
analyses from mice with melanoma tumor treated with encapsulated LM(pSecTag) cells, sustaining that there is no endostatin in the tissues
adjacent to the device; (D) Immunohistochemical analyses from mice with melanoma tumor treated with encapsulated LM(pSecTag-end) cells,
indicating the presence of endostatin in the stroma adjacent to the device which was implanted with endostatin-expressing cells. The reaction
that shows up in the cells inside the device is due to an unspecific binding. The reaction in the adjacent tissue is due to the presence of
endostatin . (i)- region inside the device; (m)- membrane; (o)- region outside the device.
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the solid form of the Ehrlich tumor presents much
lower vascularization rates. The more vascularized the
tumor, the higher the probability of obtaining tumor
regression by treatment with angiogenesis suppression
factors [16-18]. It has already been suggested that,
besides the classical antiangiogenic effect of endostatin,
a second mechanism may also be implied in endostatin-
dependent tumor regression, associated with tumor infil-
tration of leucocytes promoted by leukocyte-endothe-
lium interactions, indicating that a combination of both
these effects leads to tumor regression [19,20]. Histology
of Ehrlich tumors showed that besides necrosis, tumors
of the treated group also displayed more leukocyte infil-
tration (data not shown). More studies should be con-
ducted to verify this relationship.
The effect of endostatin produced by LM(pSecTag-
end) cells on melanoma neovascularization in mice
was determined by analysis of the vascular structures.
As m a l l e rn u m b e ro fv a s c u l a rs t r u c t u r e sw e r eo b t a i n e d
in the mice treated with the endostatin-expressing cells
compared with the control mice. The number of func-
tional vessels in the tumor area was also smaller in the
treated mice. In order to confirm “in vivo” endostatin
expression by the cells within the devices, imunohisto-
chemistry was accomplished. The presence of endo-
statin in the tissues adjacent to the device was
demonstrated, showing production, liberation and dif-
fusion of this protein to the stroma in the vicinity of
the device. These results endorse the hypothesis that
tumor regression was obtained by action of the endo-
statin released by the immunoisolated cells expressing
this protein.
Regarding the comparison between treatment using
non-encapsulated cells or cells wrapped up in alginate
microcapsules [6,7,9,10], the advantages of the use of
macroencapsulated cells are: (1) the possibility of
removing the devices in the case of adverse reactions or
at the end of the treatment; (2) escape of potentially
tumorigenic endostatin producing cells from the macro-
capsules is virtually impossible; (3) the system described
herein allows the use of universal allogeneic endostatin
producer cells, avoiding the host’s immune rejection.
Studies using the Theracyte™ system were performed
mainly by implantating islets for diabetes treatment
[21-25]. Brauker and cols [12]. employed an immunoiso-
lation device with a bi-laminated PTFE membrane, simi-
lar to the one used in the Theracyte™ system, and
demonstrated that immunoisolated allograft or isographs
survived for one year, while xenografts were destroyed
within 3 weeks. This was explained by possible xeno-
g e n i ct i s s u ek i l l i n gt h r o u g h the local accumulation of
inflammatory cells, mediated by liberation of antigens
from the Theracyte immunoisolation device and
presentation by an indirect pathway. High viability of
recombinant isogenic or allogenic cells expressing ery-
thropoietin in Theracyte™ devices one year after implan-
tation of the capsule without evidences of immune
response [26] was also described. In the present work
we used isogenic cells (LM (tk
-)) for the treatment of
C3H-HePas mice, while allogenic ones were employed
to treat C57Bl/6 mice. The small viability time of the
cells inside the immunoisolation devices is not asso-
ciated with host rejection, because this fact was
observed even when isogenic cells were implanted. Also,
cells of the immune system were not observed in the
vicinity of the device. A possibility for future studies is
the implantation of a new device containing LM(pSec-
Tag-end) cells after some time. Alternatively, the peri-
odic injection of endostatin-expressing cells within the
devices could be investigated.
Conclusions
This is the first demonstration of the use of macroen-
capsulated engineered cells for delivery of anti-angio-
genic factors, such as endostatin, in tumor treatment.
The data demonstrate that, despite the low viability of
encapsulated cells at the end of the treatment, geneti-
cally engineered encapsulated cells provide a viable vehi-
cle for the delivery of endostatin for antiangiogenic
treatment of tumors.
Methods
Cells and Culture
B16-F10 cells, belonging to a highly malignant mela-
noma cell line derived from a tumor that arose sponta-
neously in a C57BL/6 mouse, were obtained from
ATCC (CRL-6475™, Manassas, VA, USA) and cultured
with Dulbecco’s modified Eagle’s medium DMEM (Cul-
tilab, Campinas, Brazil) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco, Invitrogen, Grand
Island, NY, USA), 100 U/mL penicillin (Gibco, Invitro-
gen, Grand Island, NY, USA), 50 mg/mL streptomycin
(Gibco, Invitrogen, Grand Island, NY, USA), 2 mM
L-glutamine (Gibco, Invitrogen, Grand Island, NY,
USA), 2.5 μg/mL amphotericin B, (Gibco, Invitrogen,
Grand Island, NY, USA), 2.2 g/L sodium bicarbonate
(Gibco-BRL, Gathersburg, USA), and 110 mg/L sodium
piruvate (Gibco, Invitrogen, Grand Island, NY, USA).
Cells were routinely cultured in 250 mL T-flasks and
incubated at 37°C in a humidified 5% CO2 atmosphere.
For melanoma development, C57Bl/6 mice were injected
s.c. with 10
6 B16-F10 murine melanoma cells in the
pads of their feet. Palpable tumors appeared within 10-
15 days after injection.
Ehrlich tumor cells were maintained in ascite in C3H
(HePAS) mice. For the development of solid tumors, the
ascitic liquid was withdrawn, the cells were washed in
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6 tumor cell were injected s.c. in
the pads of the C3H mice feet.
LM Murine Fibroblasts (ATCC n°: CCL-1.3™, Mana-
ssas, VA, USA), transfected with either the empty pSec-
Tag vector (Invitrogen, Carlsbad, CA, USA) or the
pSecTag-end that contains the murine endostatin gene
(ATCC, n. 63404, Manassas, VA, EUA), were selected
with 600 μg/mL hygromycin (Invitrogen, Carlsbad, E.U.
A) for 14 days. The LM(pSecTag-end) cells presented
an expression of 0.4 μg murine endostatin/10
6 cells/24
hours and were maintained in the same conditions as
those described for the B16-F10 cells.
Animals
The animal experiments were approved by the IPEN
ethics committee for animal research (CEPA - protocol
number: 18). Male C57BL/6 and C3H-HePas mice
aged 6-10 weeks were used. They were acclimatized,
caged in groups of up to five animals in a barrier care
facility, and fed with animal chow and water ad libi-
tum. C57Bl/6 and C3H mice were subcutaneously
injected in the pads of their mice feet with 10
6 B16-
F10 murine melanoma cells or 4 × 10
6 Ehrlich cells,
respectively, in a volume of 0.2 mL sterile phosphate
buffered saline solution (PBS). Mice feet were mea-
sured every two or three days with an electronic cali-
per (YT203, Digimes Yato Pro-Cal, Guangdong,
China), and the tumor thickness was obtained by cal-
culating the differences between the measures of the
tumor-bearing and the normal feet.
Tumor treatment using endostatin producer cells
Three distinct protocols to evaluate tumor treatment
with endostatin producer cells were employed. In the
first one, 10
7 LM(pSecTag-end) cells, containing the
murine endostatin gene, were “freely” injected into the
v e n t r a lr e g i o ni nav o l u m eo f2 0μLD M E Mm e d i u m
after melanoma or Ehrlich tumor growth to 0.5 mm
thickness. In the second protocol, performed for mela-
noma or Ehrlich tumor-bearing mice, the Theracyte™
immunoisolation capsules were pre-implanted s.c. in the
back of the animals and, after wound healing and tumor
growth to 0.5 mm thickness, 10
7 LM(pSecTag-end) cells
were injected into the immunoisolation device. A third
procedure, performed only for melanoma-bearing mice,
involved implantation of the immunoisolation capsule
already containing 10
7 LM(pSecTag-end) cells in the
animals, after tumor thickness had reached 0.5 mm.
Loading endostatin expressing cells into a Theracyte™
capsule and its implantation in the animals
A Theracyte™ capsule (Baxter Healthcare, Deerfield, IL)
with a nominal internal volume of 20 μLw i t h i na
polytetrafluoroethylene (PTFE), bilayer membrane wall
was employed. Theracyte™ capsules were sterilized using
100%, 70% ethanol and sterile normal saline washes.
Mice were anaesthetized with a mixture of ketamine
(65 mg/kg) and xylazine (5 mg/Kg), and the dorsal area
was swabbed with betadine. As mentioned in the former
section, two implantation procedures were adopted. In
the first procedure, a dorsal midline incision was made
in the animal skin, a pocket was created by blunt dissec-
tion with a hemostat, and the devices (with the port
entrance sealed by means of a silicon adhesive) were
inserted into the back of the animal. The incision was
then closed by surgical suture. Another surgery was car-
ried out after wound healing, tumor growth and suitable
neovascularization around the device (approximately 14
days later), so that a suspension of 10
7 cells expressing
endostatin (treated animals) or a suspension containing
10
7 LM(pSecTag) cells (mock-treated animals) was
injected into the pre-implanted device with the aid of a
Hamilton syringe. In the second implantation procedure,
tumor cells were injected into the animal prior to cap-
sule implantation. When tumor thickness had reached
approximately 0.5 mm, 10
7 cells were injected into the
immunoisolation devices, which were then sealed and
implanted in the subcutaneous site of anesthetized
animals.
Histology and immunohistochemistry analysis
Animals were killed at the end of the experiment. The
devices were excised, washed in PBS, fixed in PBS-buf-
fered 3.7% formalin for 24 h, and processed according
to routine histopathological protocols. The histological
analysis was performed in 4-μm sections stained with
hematoxylin and eosin. For the immunohistochemical
detection of endostatin, sections of the devices were
processed and subjected to the antigen retrieval method
using anti-endostatin antibody (Anti - Rabbit AB1880,
Chemicon, EUA), followed by development with a dia-
minobenzidine-based detection system (SuperPicture
Poly HRP conjugated, Zymed, CA), according to routine
histopathological protocols.
For the angiogenic analysis, the animals treated with
non-encapsulated LM cells were euthanized after one
week of treatment. Tumors were excised, fixed, and
embedded. The microvascular density was measured
using the anti-CD34 antibody (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA) and quantified by com-
paring the number of grid intersections overlaying the
vascular structures, the functional vascular structure, or
the vascular area with the tumor region of the fields
embodying the tumor area of each animal. In all the
cases, the images were collected using the Digital Cam-
era DXM1200F, Nikon.
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